Premium
Rubicon Research Ltd, a pharmaceutical products developer that is majority owned by private equity firm General Atlantic, has struck a deal to acquire a manufacturing facility even as it gears up to float an initial public offering. Rubicon, which filed draft documents for the IPO in July 2024 and received regulatory ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
